Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.3M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $1.05M in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −11 vs. previous quarter
- 104
- 13F valueReported value at the end of Q2 2026
- $24.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CRDF, Q2 2026
No superinvestor reported holding CRDF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cardiff Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 (view filing)4:03 PM ET | Jul 14 | 2 days | Pace Gary WDirector | PPurchase | +687.3K | $1.46 | +$1.00M | +50.7%2.04M after | |
| Jul 16, 2026 (view filing)4:03 PM ET | Jul 14 | 2 days | Pace Gary WDirector | PPurchase | +687.3K | $0.00 | $0 | –687.3K after | Derivative |
| Jul 16, 2026 (view filing)4:01 PM ET | Jul 14 | 2 days | Mohindru ManiChief Executive Officer | PPurchase | +34.4K | $1.46 | +$50.0K | +139.1%59.1K after | |
| Jul 16, 2026 (view filing)4:01 PM ET | Jul 14 | 2 days | Mohindru ManiChief Executive Officer | PPurchase | +34.4K | $0.00 | $0 | –34.4K after | Derivative |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Mohindru ManiChief Executive Officer | PPurchase | +24.7K | $1.21 | +$29.9K | New position24.7K after | |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Pace Gary WDirector | PPurchase | +30.0K | $1.22 | +$36.6K | +2.3%1.36M after | |
| Jul 31, 2025 (view filing) | Jul 30 | 1 day | Pace Gary WDirector | PPurchase | +275.0K | $2.45 | +$673.8K | +26.0%1.33M after | |
| Jul 31, 2025 (view filing) | Jul 30 | 1 day | Pace Gary WDirector | PPurchase | +15.0K | $2.45 | +$36.8K | +1.1%1.35M after | |
| Dec 18, 2024 (view filing) | Dec 16-18 | 2 days | Levine James E.Chief Financial Officer | PPurchase | +7.72K | $4.76 | +$36.7K | +12.9%67.7K after | 3 lots |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Tannenbaum Renee PDirector | PPurchase | +10.0K | $3.42 | +$34.2K | +100.0%20.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cardiff Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Laurion Capital Management LP | 3,098,299 | $4.03M | 0.29% | +451,561+17.1% | Added |
| Vanguard Capital Management LLC | 2,895,592 | $3.76M | 0.00% | +39,626+1.4% | Added |
| Pfizer Inc | 2,411,575 | $3.01M | 1.77% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,205,803 | $1.57M | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 972,873 | $1.26M | 0.00% | −3,008,514−75.6% | Reduced |
| Blair William & Co | 912,513 | $1.19M | 0.00% | −9,894−1.1% | Reduced |
| Geode Capital Management, LLC | 820,062 | $1.07M | 0.00% | −779,601−48.7% | Reduced |
| UBS Group AG | 638,699 | $830.3K | 0.00% | +238,123+59.4% | Added |
| Jane Street Group, LLC | 607,900 | $790.3K | 0.00% | +567,795+1,415.8% | Added |
| Vanguard Fiduciary Trust Co | 410,602 | $533.8K | 0.00% | −35,623−8.0% | Reduced |